Xarelto Lawsuit News: Federal Bellwether Trials Set to Begin in February 2017, Bernstein Liebhard LLP Reports

September 22, 2015 - The federal litigation overseeing hundreds of Xarelto lawsuits (http://www.xareltolawsuit2015.com/) has established a schedule for the proceeding's bellwether trials. According to a Case Management Order issued in the U.S. District Court, Eastern District of Louisiana, the first of the four Xarelto trials is to begin on February 6, 2017, followed by a second that will commence on March 13, 2017. The litigation's third bellwether trial is scheduled to start on April 24, 2017, while the final trial will get underway on May 30, 2017. The first two trials will be convened in the Eastern District of Louisiana. The third and fourth will take place in yet-to-be determined Districts in Mississippi and Texas. (In Re: Xarelto Products Liability Litigation, No. 2592)

The Order further stipulates that 40 representative Xarelto cases will be selected for an initial bellwether discovery pool by January 11, 2016. Ten will be chosen by plaintiffs, 10 by the defense, and 20 at random. Cases from the discovery pool will be proposed for bellwether selection by August 1, 2016.

"Our Firm is representing a number of Xarelto plaintiffs who allegedly experienced uncontrollable bleeding and other serious complications related to its use. This series of trials is extremely important, as bellwether cases are intended to provide insight into how other juries might rule in similar lawsuits," says Sandy A. Liebhard, a partner at Bernstein Liebhard LLP, a nationwide law firm representing victims of defective medical devices and drugs. The Firm continues to evaluate potential Xarelto lawsuits on behalf of individuals who may have been harmed by this blood-thinning medication.

Xarelto Litigation
According to court documents, at least 1,694 Xarelto lawsuits are currently pending in the Eastern District of Louisiana. All of the complaints claim that the drug's manufacturers failed to provide patients and doctors with adequate warnings regarding its risks and improperly marketed the medication as a superior alternative to warfarin. Among other things, plaintiffs point out that internal hemorrhaging associated with the use of this much older blood thinner can be stopped via the administration of vitamin K. By contrast, there is currently no approved antidote to reverse Xarelto bleeding.

The U.S. Food & Drug Administration (FDA) approved Xarelto in 2011, and the medication is now indicated for the prevention of strokes in people with atrial fibrillation; the treatment of deep vein thrombosis and pulmonary embolism; and the prevention of deep vein thrombosis in patients undergoing hip or knee replacement surgery. Xarelto's label includes a black box warning that contains information about the increased risk of blood clot formation after premature discontinuation of the medication in the absence of adequate alternative anticoagulation.

Individuals who allegedly experienced uncontrollable Xarelto bleeding or other complications that could be related to its use may be eligible to join the growing litigation involving the blood thinner. Learn more about filing a Xarelto lawsuit by visiting Bernstein Liebhard LLP's website, or call 800-511-5092 to arrange for a free, no obligation case review.

About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993. As a national law firm, Bernstein Liebhard LLP possesses all of the legal and financial resources required to successfully challenge billion dollar pharmaceutical and medical device companies. As a result, our attorneys and legal staff have been able to recover more than $3.5 billion on behalf of our clients. The Firm was named by The National Law Journal to the Plaintiffs' Hot List, recognizing the top plaintiffs firms in the country, for 12 consecutive years. Bernstein Liebhard LLP is the only firm in the country to be named to this prestigious list for a dozen consecutive years.

Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092

ATTORNEY ADVERTISING. © 2015 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Contact Information:
Sandy A. Liebhard, Esq.
Bernstein Liebhard LLP
info (at)consumerinjurylawyers(dot)com
http://www.xareltolawsuit2015.com/
https://plus.google.com/115936073311125306742?rel=author